5-Sulfamoyl-benzthiazol | 21262-99-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 5-Sulfamoyl-benzthiazol
• 英文别名: 1,3-Benzothiazole-5-sulfonamide
• CAS: 21262-99-7
• 化学式: C₇H₆N₂O₂S₂
• 分子量: 214.269
• InChiKey: PUQJWRIJAQIXBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Liquid crystal composition
  申请人：Sumitomo Chemical Company, Limited

  公开号：US10336938B2

  公开（公告）日：2019-07-02

  A liquid crystal composition containing a polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain and a polymer (B) of the polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain, which inhibits occurrence of an orientation defect of a liquid crystal compound and exhibits excellent storage stability when dissolved in a solvent is provided.

  本发明提供了一种液晶组合物，其中含有主链上具有 5 个或更多环状结构的可聚合液晶化合物（A）和主链上具有 5 个或更多环状结构的可聚合液晶化合物（A）的聚合物（B），该组合物能抑制液晶化合物取向缺陷的发生，并在溶解于溶剂中时表现出优异的储存稳定性。
• ANTIMICROBIAL AGENTS
  申请人：Ranbaxy Laboratories Limited

  公开号：EP1879877A2

  公开（公告）日：2008-01-23
• LIQUID CRYSTAL COMPOSITION
  申请人：Sumitomo Chemical Company, Limited

  公开号：US20170283700A1

  公开（公告）日：2017-10-05

  A liquid crystal composition containing a polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain and a polymer (B) of the polymerizable liquid crystal compound (A) having 5 or more ring structures in its main chain, which inhibits occurrence of an orientation defect of a liquid crystal compound and exhibits excellent storage stability when dissolved in a solvent is provided.
• US4426388A
  申请人：——

  公开号：US4426388A

  公开（公告）日：1984-01-17
• [EN] ANTIMICROBIAL AGENTS<br/>[FR] AGENTS ANTIMICROBIENS
  申请人：RANBAXY LAB LTD

  公开号：WO2006117762A2

  公开（公告）日：2006-11-09

  (EN) Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly against bacterium, for example, Staphylococci, Enterococci, Streptococci, Haemophilus, Moraxalla, Escherichia, Chlamydia, Rickettsiae, Mycoplasm, Legionella, Mycobacterium, Helicobacter, Clostridium, Bacteroides, Corynebacterium, Bacillus or Enterobactericeae, and fungal organisms, for example, Aspergillus, Blastomyces, Candida, Coccidiodes, Cryptococcus, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidiodes, Pneumocystis, Trichophyton, or Trichosporium. Processes for the preparation of these compounds, pharmaceutical compositions thereof, and methods of treating microbial infections are also provided.(FR) Cette invention concerne des composés aromatiques substitués qui sont des inhibiteurs de la tRNA synthétase et qui peuvent donc être utilisés comme agents antimicrobiens. Les composés décrits ici peuvent s'utiliser pour le traitement ou la prévention d'états pathologiques provoqués ou induits par des bactéries gram positif,gram négatif, anaérobiques ou par des organismes fongiques tels que des staphylocoques, entérocoques, streptocoques, Haemophilus, Moraxalla, Eschérichia, Chlamydia, Rickettsiae, Mycoplasme, légionelle, mycobacterium, Hélicobacter, Clostridium, bacteroïdes, Corynebactérium, Bacille ou Entérobacteriacées, des organismes fongiques tels qu'Aspergillus, Blastomycètes, Candida, Coccidioides, Cryptocoque, Epidermophyton, Hendersonula, Histoplasma, Microsporum, Paecilomyces, Paracoccidioides, Pneumocystis, Trichophyton, ou Trichosporium. Sont également décrits des procédés d'obtention de ces composés, des compositions pharmaceutiques les contenant ainsi que des méthodes de traitement d'infections microbiennes.